Top Section
Top Section
India is on track for a record year of IPOs. Global tech giants continue to plough capital into a fast-growing consumer economy that is investing heavily in ensuring it’s a major player — along with the US and China — in an AI-first world
◆ Deal finds demand despite arrest of South Korea's president ◆ High single digit concession left for investors ◆ Leads added spread to calm concerns
South Korean policy lender kickstarts 2025 funding following a month of political chaos
More articles
More articles
More articles
-
Société Générale was set to launch a popular additional tier one deal in the dollar market on Thursday, as investors spied an opportunity to gain a little pick-up over other French bank credits. -
Renewed concerns over Chinese chipmaker Tsinghua Unigroup Co’s debt repayment abilities led to sharp drops in its onshore and offshore bonds this week. Addison Gong reports.
-
StanChart's Sameer Chandra has died — ICBC Asia syndicate boss leaves — RHB names two senior posts — UBS chooses India head — StanChart's Robins retires — HKMA, IFC team up for green finance
-
Gland Pharma has completed India’s largest pharmaceutical IPO, a Rp65bn ($870.6m) deal that sailed through on demand from institutional accounts. But the issuer’s Chinese ties and a wobble in pharma stocks blunted retail investor interest. Jonathan Breen reports.
-
Chinese property borrowers are increasingly taking a strategic approach to managing their liabilities by tendering old notes when new bonds are announced. The trend has taken off this year, and is set to be the norm as issuers become more proactive in tackling their refinancing needs sooner rather than later. Morgan Davis reports.
-
A handful of borrowers have been forced to close smaller loans than expected recently amid waning interest from lenders. While bankers insist there is still plenty of liquidity, debut credits and infrequent borrowers are feeling the pinch in the pandemic. Pan Yue reports.
shared comment list
